Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2–11 years in Malaysia: A randomized, placebo-controlled, Phase III study
Open Access
- 1 December 2013
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 31 (49), 5814-5821
- https://doi.org/10.1016/j.vaccine.2013.10.013
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Immunogenicity and safety of tetravalent dengue vaccine in 2–11 year-olds previously vaccinated against yellow fever: Randomized, controlled, phase II study in Piura, PeruVaccine, 2012
- From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccineVaccine, 2011
- Vaccines for the prevention of dengue: Development updateHuman Vaccines, 2011
- Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: Randomized controlled phase I trial in the PhilippinesVaccine, 2011
- Development of sanofi pasteur tetravalent dengue vaccineHuman Vaccines, 2010
- A Novel Tetravalent Dengue Vaccine Is Well Tolerated and Immunogenic against All 4 Serotypes inFlavivirus‐Naive AdultsThe Journal of Infectious Diseases, 2010
- Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis virusesVaccine, 2010
- Live Attenuated Chimeric Yellow Fever Dengue Type 2 (ChimeriVax™-DEN2) Vaccine: Phase I Clinical Trial for Safety and Immunogenicity: Effect of Yellow Fever Pre-immunity in Induction of Cross Neutralizing Antibody Responses to AllHuman Vaccines, 2006
- Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever-Dengue Virus Tetravalent VaccineJournal of Virology, 2001
- Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus Is Immunogenic and Protective in Nonhuman PrimatesJournal of Virology, 2000